You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.
With the partnership, the companies aim to help researchers streamline their workflows from sample collection to enrichment to interpretation.
The multi-omics analytics company is assisting drug discovery and precision medicine as the first partner of Mayo's Clinical Data Analytics Platform.
The group aims to develop a transcriptomic and epigenetic biomarker assay for early detection and relapse monitoring in colorectal cancer patients.
Ongoing Scripps research into polygenic risk for coronary artery disease now offers remote genetic counseling as well as an Android app.
GTC will sequence samples and help with technical and clinical validation, while C2i will perform AI-based analysis of the data, recruit samples, and perform other clinical trial activities.
The Mayo Clinic Platform, now headed by John Halamka, will lean on Nference for multi-omics analytics to inform biomedical R&D and postmarketing surveillance.
Mayo Clinic Ventures and NTT Venture Capital have invested in the AI software developer to synthesize biomedical data for drug development and precision medicine.
In Nature this week: artificial intelligence system is better at spotting breast cancer than experts and a universal sample multiplexing method for single-cell RNA sequencing.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.